Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial

OBJECTIVES: To assess the effects of filgotinib on inflammatory and structural changes at various spinal locations, based on MRI measures in patients with active AS in the TORTUGA trial. METHODS: In the TORTUGA trial, patients with AS received filgotinib 200 mg (n = 58) or placebo (n = 58) once dail...

Descripción completa

Detalles Bibliográficos
Autores principales: Maksymowych, Walter P, Østergaard, Mikkel, Landewé, Robert, Barchuk, William, Liu, Ke, Gilles, Leen, Hendrikx, Thijs, Besuyen, Robin, Baraliakos, Xenofon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157176/
https://www.ncbi.nlm.nih.gov/pubmed/34647992
http://dx.doi.org/10.1093/rheumatology/keab758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157176/
https://www.ncbi.nlm.nih.gov/pubmed/34647992
http://dx.doi.org/10.1093/rheumatology/keab758

Ejemplares similares